CTU: Randomized, Double-Blind, International Multicenter, Parallel-Controlled Phase III Clinical Study to Evaluate Recombinant Anti-RANKL Human Monoclonal Antibody Injection (HLX14) Versus Denosumab Injection (Prolia®) in Postmenopausal Women with Osteoporosis at High Risk of Fracture

  • Preda, Veronica (Primary Chief Investigator)
  • Chester, Catherine (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleHLX14-002-PMOP301
AcronymHLX14-002-PMOP301
StatusActive
Effective start/end date18/07/22 → 17/07/27